Monolithic matrix transdermal delivery system for administering molsidomine
US5962013A · kind A · utility
10Cited by
35References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 4, 1998 |
| Grant date | Oct 5, 1999 |
| Priority date | — |
| Expiry date | Aug 4, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/5377
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides monolithic matrix formulations for transdermal administration of molsidomine. The device includes a copolymer of 2-ethylhexyl acrylate, 2-hydroxyethylmethacrylate, and methacrylic acid. The invention also provides transdermal devices having a monolithic matrix made using such a formulation in combination with an active ingredient and a vehicle or vehicle formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.